Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Intensity TherapeuticsINTS +4.80%32 3-Year EBITDA Growth Rate is 14.90% as of Jun. 2026. GuruFocus rates INTS with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 1,130 Biotechnology companies, Intensity Therapeutics ranks better than 50% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 14.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -8.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Intensity Therapeutics was 14.90% per year. The lowest was -51.60% per year. And the median was -23.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Intensity Therapeutics 3-Year EBITDA Growth Rate Related Terms
INTS vs CALC, INAB, PHIO: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Intensity Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intensity Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intensity Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Intensity Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 14.90% mean?
Intensity Therapeutics (INTS) has a 3-Year EBITDA Growth Rate of 14.90% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Intensity Therapeutics and its competitors. According to the industry distribution chart, Intensity Therapeutics ranks #565 out of 1130 companies in the Biotechnology industry, placing it in the top 50%.
Is Intensity Therapeutics' 3-Year EBITDA Growth Rate too high?
Intensity Therapeutics' current 3-Year EBITDA Growth Rate is 14.90%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Intensity Therapeutics' value of 14.90% is 0.3% above this industry median. Based on the distribution chart, Intensity Therapeutics ranks #565 out of 1130 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Intensity Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Intensity Therapeutics' 3-Year EBITDA Growth Rate compare to CALC and INAB?
According to the Biotechnology industry distribution chart, Intensity Therapeutics ranks #565 out of 1130 companies for 3-Year EBITDA Growth Rate. This puts Intensity Therapeutics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. Intensity Therapeutics' value of 14.90% is 0.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Intensity Therapeutics's current 3-Year EBITDA Growth Rate of 14.90% is 0.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Intensity Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intensity Therapeutics's current 3-Year EBITDA Growth Rate is 14.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intensity Therapeutics stock overvalued right now?
Intensity Therapeutics (INTS) has a current 3-Year EBITDA Growth Rate of 14.90%. The current 3-Year EBITDA Growth Rate is 14.90% and 0.3% above the Biotechnology industry median of 14.85. Intensity Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Intensity Therapeutics (INTS), the current 3-Year EBITDA Growth Rate is 14.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
32GF Score
Get the complete analysis for INTS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INTS has been successfully added to your 
